gsk2838232
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 18, 2013 (NCT01802918)
Timeline
Indications
Studied for
Mechanism of action
- HIV-1 proteaseINHIBITOR
inhibitor - HIV-1
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@@]2([C@@H](O)CN(CCN(C)C)Cc2ccc(Cl)cc2)CC1=O- Mol. weight
- 809.57 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4303141 ↗
Also known as
- gsk2838232
- gsk2838232
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03234036 | Phase 1 | Aug 2, 2017 | GlaxoSmithKline |
| NCT03045861 | Phase 2 | Mar 17, 2017 | GlaxoSmithKline |
| NCT02795754 | Phase 1 | Mar 1, 2016 | GlaxoSmithKline |
| NCT02289495 | Phase 1 | Nov 18, 2014 | GlaxoSmithKline |
| NCT02289482 | Phase 1 | Nov 17, 2014 | GlaxoSmithKline |
| NCT01802918 | Phase 1 | Feb 18, 2013 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2013 |
1 organizations
Page 1 / 1